logo

Audentes Therapeutics, Inc. (BOLD)



Trade BOLD now with
  Date
  Headline
10/10/2018 8:36:38 PM Audentes Therapeutics Announces Pricing Of Its Underwritten Public Offering Of 5.20 Mln Shares At $29.00/shr
10/9/2018 4:21:08 PM Audentes Therapeutics Announces Proposed Public Offering Of Common Stock
10/8/2018 6:42:00 AM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) FY18 Estimate To -3.50 From -2.98
10/8/2018 6:41:22 AM Wedbush Is Cutting Audentes Therapeutics, Inc. (BOLD) Q4 18 Estimate To -0.99 From -0.76
10/8/2018 6:41:08 AM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q3 18 Estimate To -0.93 From -0.74
10/8/2018 6:39:47 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $52 Up From $49 Price Target
10/5/2018 8:11:53 AM Audentes Therapeutics To Provide Update On New Positive Interim Data From ASPIRO, The Phase 1/2 Clinical Trial Of AT132
10/5/2018 8:10:47 AM Audentes Therapeutics Presents New Positive Interim Data From ASPIRO
8/21/2018 8:05:58 AM Audentes Announces Regenerative Medicine Advanced Therapy Designation Granted By The FDA To AT132
8/8/2018 9:40:37 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $49 Price Target
8/7/2018 6:15:22 AM Audentes Therapeutics Q2 Net Loss $31.4 Mln Vs $22.7 Mln Last Year
6/5/2018 8:08:53 AM Audentes Announces Priority Medicines (PRIME) Designation Granted By EMA To AT132 For F X-Linked Myotubular Myopathy
5/17/2018 7:18:00 AM Wedbush Reiterates Audentes Therapeutics, Inc. (BOLD) At Outperform With $49 Price Target
5/10/2018 9:51:57 AM Wedbush Is Increasing Audentes Therapeutics, Inc. (BOLD) FY18 Estimate To -2.98 From -3.07
5/10/2018 9:51:40 AM Wedbush Is Raising Audentes Therapeutics, Inc. (BOLD) Q4 18 Estimate To -0.76 From -0.79